EQUITY RESEARCH MEMO
Biodeal Pharmaceuticals
Generated 5/24/2026
Executive Summary
Conviction (model self-assessment)65/100
Biodeal Pharmaceuticals is an Indian WHO-GMP certified CDMO specializing in small-molecule finished dosage forms, nasal sprays, nutraceuticals, and herbal products. Founded in 2007 and headquartered in Ahmedabad, the company leverages advanced formulation expertise and regulatory approvals (PIC/S, WHO-GMP) to serve domestic and international pharma brands. With 200-500 employees, it offers end-to-end manufacturing services, positioning itself as a key player in the growing contract manufacturing space, particularly in nasal drug delivery and nutraceuticals. The company's focus on high-demand segments and regulatory compliance provides a stable revenue base, though its private status limits visibility into financials.
Upcoming Catalysts (preview)
- Q2 2027Expansion of Nasal Spray Manufacturing Capacity70% success
- Q4 2026New PIC/S Certification for Additional Facility80% success
- Q3 2026Strategic Partnership with Global Pharma Brand for Herbal Products60% success
Locked sections
- · Pipeline Analysis
- · Competitive Landscape
- · Catalyst Calendar (full 12-month)
- · Bull Case
- · Bear Case
- · Counterfactual Scenarios
- · Valuation Notes
- · SEC Filing Highlights
- · Insider Activity
- · Literature Watch
- · Patent Landscape
- · Mechanism Cluster Map
- · Audio Briefing (5 min)